Abstract | PURPOSE: EXPERIMENTAL DESIGN:
IgE were determined with a commercially available ELISA kit in 201 MM patients at diagnosis, 144 subjects with MGUS, and 77 age-matched controls. RESULTS:
IgE levels progressively decreased from controls to MGUS and from MGUS to MM (P = 0.001). MM patients with IgE levels of >11.5 IU/mL (median) had a better survival than patients with IgE of <11.5 IU/mL (P = 0.048). The difference was even more significant when MM patients were divided according to clinical cutoff values. Patients with elevated IgE levels (>100 IU/mL) had from 2 to 3 years longer survival than those with low (<10 IU/mL) or intermediate values (10-100 IU/mL; P < 0.01). IgE levels were positively and negatively correlated with hemoglobin (P = 0.006) and beta2-microglobulin levels (P = 0.007), respectively. Univariate and multivariate analyses confirmed that high IgE levels are positive predictors of overall survival (P = 0.03 and 0.08, respectively) and strongly correlated with hemoglobin values. CONCLUSIONS: Because IgE levels are dependent on Th(2) responses, these data open new perspectives in the interpretation of antitumor immune responses and pathogenesis of anemia in MM.
|
Authors | Giorgia Maria Elena Matta, Silvano Battaglio, Cristiana Dibello, Patrizia Napoli, Cristina Baldi, Giovannino Ciccone, Marta Coscia, Mario Boccadoro, Massimo Massaia |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 13
Issue 18 Pt 1
Pg. 5348-54
(Sep 15 2007)
ISSN: 1078-0432 [Print] United States |
PMID | 17875762
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hemoglobins
- Immunoglobulin E
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Hemoglobins
(analysis)
- Humans
- Immunoglobulin E
(blood)
- Male
- Middle Aged
- Multiple Myeloma
(mortality)
- Paraproteinemias
(immunology)
- Prognosis
|